miltefosine 50 MG Oral Capsule

RxCUI
1494071
RxNorm name
miltefosine 50 MG Oral Capsule
Display name
Miltefosine (Oral Pill)
Full name
miltefosine 50 MG Oral Capsule
Term type
SCD
Status
Active
Strength
50 mg
Dose form
Cap
Route
Oral Pill
Updated
2026-10-04 02:02:29

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
052014
Active start
052014
Multiple ingredient
NO
Branded
NO

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
miltefosine50 MG / 1 EACHmiltefosinemiltefosine

Dose Form Concepts#

Dose form, RxCUI table
Dose formRxCUI
Oral Capsule316965

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
miltefosine1494066

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRmiltefosine 50 MG Oral Capsule1NAMES
RxNorm Namemiltefosine 50 MG Oral Capsule1NAMES
TTYSCD1ATTRIBUTES
RxCUI14940711CODES
MMSL_CODECD260551CODES

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
IMPAVIDOMILTEFOSINEProfounda, Inc.bcb387ac-2e90-4f5e-94b2-d3635190678e2026-09-30Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 1494071

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
bcb387ac-2e90-4f5e-94b2-d3635190678emiltefosine 50 MG Oral Capsule [PSN] · miltefosine 50 MG Oral Capsule [SCD]213These highlights do not include all the information needed to use IMPAVIDO safely and effectively. See full prescribing information for IMPAVIDO. IMPAVIDO (miltefosine) capsules, for oral use Initial U.S. Approval: 201420251218

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCP01CXOther agents against leishmaniasis and trypanosomiasisATC1-4miltefosine
FDASPLN0000190851AntileishmanialEPChas_epcmiltefosine
MEDRTD010767PhosphorylcholineCHEMhas_ingredientmiltefosine
MEDRTD004342Drug HypersensitivityDISEASEci_withmiltefosine
MEDRTD016773Leishmaniasis, CutaneousDISEASEmay_treatmiltefosine
MEDRTD007898Leishmaniasis, VisceralDISEASEmay_treatmiltefosine
MEDRTD011247PregnancyDISEASEci_withmiltefosine
MEDRTD016111Sjogren-Larsson SyndromeDISEASEci_withmiltefosine
MEDRTN0000181812Lysophospholipid Receptor InteractionsMOAhas_moamiltefosine

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESAVAILABLE_STRENGTH50 MG
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESHUMAN_DRUGUS
ATTRIBUTESRXNAV_HUMAN_DRUGUS
ATTRIBUTESSCHEDULE0
CODESSNOMEDCT890469003
CODESVUID4035637
NAMESPrescribable Synonymmiltefosine 50 MG Oral Capsule
SOURCESSourceMicromedex RED BOOK
SOURCESSourceMultum MediSource Lexicon
SOURCESSourceNational Drug Data File Plus Source Vocabulary
SOURCESSourceUS Edition of SNOMED_CT
SOURCESSourceVeterans Health Administration National Drug File